---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050212"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:57:17.564436+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BriaPro reports Q1 net loss of $82K; cash at $1; going concern uncertainty

## Summary
- Net loss $82,123 for three months to Oct 2024 vs $128,026 loss in prior year period.
- Total assets $195,979; intangible assets (patents) net $195,978.
- Current liabilities $522,835; shareholders' deficit $487,817; cash unchanged at $1.
- Due to BriaCell (related party) $503,709; no revenue or commercial operations.
- Going concern doubt due to pre-clinical stage and need for additional financing.

## SEC filing metadata
- accession: 0001493152-24-050212
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224050212/0001493152-24-050212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224050212/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050212
- JSON: https://secwatch.observer/filing/0001493152-24-050212.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.